AETERNA ZENTARIS INC (AEZS) Stock Price, Quote, News and Overview
NASDAQ:AEZS - Nasdaq - CA0079756007 - Common Stock - Currency: USD
AEZS Quote, Performance and Key Statistics
NASDAQ:AEZS (8/8/2024, 8:00:00 PM)
5.72
+0.32 (+5.93%)
The current stock price of AEZS is 5.72 USD. In the past month the price decreased by -16.86%. In the past year, price decreased by -51.69%.
AEZS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About AEZS
Company Profile
Aeterna Zentaris Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The firm is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The firm's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.
Company Info
AETERNA ZENTARIS INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO 29486 CA
CEO: Paulini Klaus
Employees: 21
Company Website: https://www.zentaris.com/
Phone: 18439003201
AETERNA ZENTARIS INC / AEZS FAQ
What is the stock price of AETERNA ZENTARIS INC today?
The current stock price of AEZS is 5.72 USD. The price increased by 5.93% in the last trading session.
What is the ticker symbol for AETERNA ZENTARIS INC stock?
The exchange symbol of AETERNA ZENTARIS INC is AEZS and it is listed on the Nasdaq exchange.
On which exchange is AEZS stock listed?
AEZS stock is listed on the Nasdaq exchange.
What is AETERNA ZENTARIS INC worth?
AETERNA ZENTARIS INC (AEZS) has a market capitalization of 17.51M USD. This makes AEZS a Nano Cap stock.
How many employees does AETERNA ZENTARIS INC have?
AETERNA ZENTARIS INC (AEZS) currently has 21 employees.
What are the support and resistance levels for AETERNA ZENTARIS INC (AEZS) stock?
AETERNA ZENTARIS INC (AEZS) has a support level at 5.43 and a resistance level at 5.98. Check the full technical report for a detailed analysis of AEZS support and resistance levels.
Is AETERNA ZENTARIS INC (AEZS) expected to grow?
The Revenue of AETERNA ZENTARIS INC (AEZS) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the AEZS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AETERNA ZENTARIS INC (AEZS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AEZS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AEZS, evaluating the profitability, health, valuation and growth aspects
- AETERNA ZENTARIS INC (AEZS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AETERNA ZENTARIS INC (AEZS) Sales and EPS estimates to see what analysts future expectations are.
- AETERNA ZENTARIS INC (AEZS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AETERNA ZENTARIS INC (AEZS) Insider and Institutional Ownership to learn about the owners and their transactions.
- AETERNA ZENTARIS INC (AEZS) Stock Chart to make your own analysis
- AETERNA ZENTARIS INC (AEZS) Latest news and press-releases to stay up to date.
Does AETERNA ZENTARIS INC (AEZS) stock pay dividends?
AEZS does not pay a dividend.
When does AETERNA ZENTARIS INC (AEZS) report earnings?
AETERNA ZENTARIS INC (AEZS) will report earnings on 2024-11-07, before the market open.
What is the Price/Earnings (PE) ratio of AETERNA ZENTARIS INC (AEZS)?
AETERNA ZENTARIS INC (AEZS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11).
AEZS Technical Analysis
AEZS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEZS. AEZS may be in some trouble as it scores bad on both profitability and health.
AEZS Financial Highlights
Over the last trailing twelve months AEZS reported a non-GAAP Earnings per Share(EPS) of -11. The EPS decreased by -274.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.8% | ||
| ROE | -139.22% | ||
| Debt/Equity | 0.01 |
AEZS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AEZS. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 68.75% and a revenue growth -2.27% for AEZS